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ABSTRACT 
The COVID-19 pandemic has caused significant shifts in patient care including a steep decline in 
ambulatory visits and a marked increase in the use of telemedicine.  Infantile hemangiomas can 
require urgent evaluation and risk stratification to determine which infants need treatment and 
which can be managed with continued observation.  For those requiring treatment, prompt 
initiation decreases morbidity and improves long-term outcomes.  The Hemangioma Investigator 
Group has created consensus recommendations for management of infantile hemangiomas via 
telemedicine.   FDA/EMA approved monitoring guidelines, clinical practice guidelines and 
relevant, up-to-date publications regarding initiation and monitoring of beta-blocker therapy 
were used to inform the recommendations. Clinical decision-making guidelines about when 
telehealth is an appropriate alternative to in-office visits, including medication initiation, dosage 
changes, and ongoing evaluation are included. The importance of communication with 
caregivers in the context of telemedicine is discussed and online resources for both hemangioma 
education and for propranolol therapy provided.      
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Introduction: 
The novel coronavirus (COVID-19) pandemic has drastically altered healthcare delivery 
including widespread reductions in ambulatory visits to minimize exposure to and transmission 
of COVID-19 resulting in unprecedented adoption of virtual care via telemedicine platforms. In 
light of these significant shifts in patient care, the Hemangioma Investigator Group (HIG) met 
with the goal of creating consensus recommendations to provide timely care for infants with IH 
via telehealth. The use of beta-blockers in the treatment of infantile hemangiomas (IH) has 
revolutionized care and recent American Academy of Pediatrics (AAP) clinical practice 
guidelines (CPG) emphasize that early therapeutic intervention is critical for complicated IH to 
prevent medical complications or permanent disfigurement1.  In this statement, we review 
FDA/EMA approved monitoring guidelines, information derived from several clinical practice 
guidelines, and other publications regarding initiation and monitoring of beta-blocker therapy, 
including newly published information which could help inform modification of these practices. 
We give recommendations to help guide decisions about when telehealth may be an alternative 
to in-office visits, including initiation, dosage changes, and continued evaluation for those 
patients requiring treatment.  We also provide tools for patient communication in context of 
telemedicine. While these recommendations were prompted by the COVID-19 pandemic, we 
recognize that they might be relevant in analogous settings where there is a disruption of the 
normal delivery of medical care and potentially in settings with lack of access to practitioners 
with expertise in IH management. 
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Methods  
The Hemangioma Investigator Group (HIG) met via videoconferencing on March 22, 2020, and 
subdivided members into 3 groups: one to work on the introduction and discussion, one to create 
a table of inclusion and exclusion criteria for telemedicine use of beta-blockers, and one to curate 
available patient-education materials for practitioners and parents.  Through an iterative process 
of review of these 3 components we were able to achieve unanimous consensus regarding the 
content of these recommendations.   
Risk stratification and timing of therapeutic intervention, when needed: 
The most rapid IH growth occurs between 1 and 3 months of age and there is a “window of 
opportunity” to treat problematic IHs in order to prevent morbidities. Telemedicine has a critical 
role to play in facilitating early evaluation and risk stratification. In areas where access to 
specialists has long been challenging, telemedicine triage has the potential to improve care for 
high risk IH. Early consultation, ideally by 1 month of age or as soon as high-risk features are 
recognized is warranted. Table 1, from the AAP CPG, delineates risk categories of IH and 
potential associated morbidities.  
Potential risks associated with beta-blocker treatment:  
Oral beta-blockers are the gold standard when systemic treatment is indicated for IH and 
propranolol solution is the only FDA/EMA-approved treatment. Methods for initiation of oral 
propranolol have evolved over time.  Consensus recommendations prior to the FDA/EMA 
approval in 2014 included;10  1) screening for contraindications to propranolol, 2) performing or 
obtaining documentation of, a recent normal cardiovascular and pulmonary history and 
examination, 3) obtaining key historical data including poor feeding, dyspnea, tachypnea, 
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diaphoresis, wheezing, heart murmur, or family history of heart block or arrhythmia, and 4) 
prolonged in-office monitoring. The FDA/EMA approved administration monitoring 
recommendations include in-office heart rate (HR) and blood pressure (BP) monitoring for 2 
hours after the first dose of propranolol or for increasing the dose (>0.5 mg/kg/day) for infants 5 
weeks adjusted gestational age or older. 10 11 More recent consensus statements1, 12, 13, 14 vary in 
specific recommendations for propranolol initiation. Both Australian and British guidelines13,14 
recommend full-term healthy infants without comorbidities may undergo outpatient initiation 
without in-office monitoring with initial doses of 1 mg/kg/day. 13,14  Both state that a thorough 
medical history and clinical examination including HR are prerequisites to initiation of systemic 
therapy.  A recent study by Puttgen et al 15 of 783 patients with in-office monitoring during 
medication initiation found no symptomatic bradycardia or hypotension occurred during the in-
office monitoring and minimal, clinically insignificant decrease in HR (mean decrease of 8 to 9 
beats per minute). Many practitioners have moved away from in-office monitoring for those 
infants of gestationally corrected age of 5 weeks or older with normal birth-weight unless other 
risk factors exist.    
While rare, hypoglycemia, seen primarily with intercurrent illness or decreased feeding, is a 
serious potentially life-threatening risk.16   Other risks include bronchospasm and wheezing, 
usually in the context of a respiratory illness, cold hands and feet, gastrointestinal upset, and 
sleep disturbances.  All of these potential adverse events require anticipatory guidance of 
parents, which should still be a part of clinical care, whether in person or via telemedicine.   
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Other orally administered beta blockers and topical beta blockers 
Other non-FDA approved beta-blocking agents, including oral atenolol and nadolol, have been 
used for the treatment of IH with several publications supporting their efficacy.  However, the 
group was unable to reach consensus recommendation regarding telemedicine for initiation of 
either of these medications.  Topical timolol has been widely used for treating IH with efficacy 
reported, particularly for small, superficial IH. 9,15   Systemic absorption is variable but does 
occur,17,18  suggesting that similar prescreening should be performed to assure that infants are 
healthy and have had a normal cardiovascular and pulmonary examinations e.g. via recent 
history and physical exam (see discussion below).   
RECOMMENDATIONS: 
Our recommendations regarding telemedicine initiation of beta-blocker therapy are summarized 
in Table 2 with an accompanying algorithm (Figure 1). They were developed after review of 
relative and absolute contraindications for propranolol, reported adverse events, FDA/EMA 
labelling recommendations, published guidelines, with group consensus.  They are made with the 
goal of supporting practicing clinicians in delivering high quality care in a dramatically altered 
care delivery model.  They apply primarily to new patients, but also for return patients who are 
being started on a systemic beta-blocker. 
Group 1 patients have characteristics which confer a standard risk. These infants can be 
considered as appropriate candidates for telemedicine initiation of oral or topical beta-blocker 
therapy even in the absence of an in-person visit.  Group 2 includes patients with higher risk 
characteristics, where the risk-benefit ratio favors in-person visit, not only for propranolol 
initiation but to discuss management, risk of extra-cutaneous disease, and to arrange for imaging 
A
cc
ep
te
d 
A
rt
ic
le
 
This article is protected by copyright. All rights reserved 
studies if needed.  These characteristics might be considered relative or absolute exclusion 
criteria for initiation of medication via telemedicine, particularly systemic beta-blockers, and for 
these infants, telemedicine should be used only in exceptional circumstances.   
There was broad consensus that in settings where there are not disruptions of ambulatory care 
delivery, in-person evaluation for new patients, particularly young infants, is the best approach.   
Physical examination is more thorough and may provide a more accurate assessment of baseline 
status including subtle clues (such as duskiness) suggestive of impending ulceration, and the 
presence of deeper hemangioma not evident with photographs or video without palpation.   Other 
advantages of in-person assessment include more accurate assessment of weight, confirmation of 
respiratory and cardiovascular status, and the opportunity for face-to-face counseling and 
establishing rapport with families, the latter being particularly important for infants who need 
treatment, since the medications used for IH are typically continued for many months or longer.   
The most commonly used target doses of propranolol are between 2 and 3 mg/kg/day divided 
twice daily with FDA/EMA recommendations for starting with 1 mg/kg/day and increasing 
weekly by 1 mg/kg/day to target dose.  However in the context of outpatient initiation via 
telemedicine, our group unanimously agreed that starting with a lower dose of 0.5 mg/kg/day 
divided twice daily, and increasing every 3 to 4 days by 0.5 mg/kg/day to the target dose was a 
preferred approach.  A minority commented that in a typical standard risk infant, they would 
consider starting at 1 mg/kg/day divided twice, increasing in 0.5 mg/k/day increments every 3 to 
4 days to target dosing.  
There was uniform consensus that in most cases follow-up visits can be performed via 
telemedicine either via two-way synchronous video or asynchronous store-and-forward photos 
with telephone counseling as long as it is possible to examine the infant’s hemangioma 
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adequately and to provide sufficient parental counseling . Even if video visits are used, having 
photographs of the IH uploaded shortly before a telemedicine visit is often necessary to be able 
to adequate evaluate the IH, given the variability of visualization with live-interactive portals. 
Clinical situations which may be less optimal for follow-up telemedicine visits include 
diagnostic uncertainty, unexpected IH growth, functional impairment, or significant or 
worsening ulceration.  If there is medication intolerance or lack of efficacy requiring 
consideration of another treatment modality (e.g. transition from topical to systemic therapy or 
addition of another systemic agent), then providers should consider whether a telemedicine visit 
is sufficient to address the clinical scenario or if an in-person visit is indicated.    
Use of topical timolol  
Topical timolol is efficacious for smaller, thin IH.17,19,20  Although rigorous safety studies have 
not been performed, if used in small amounts, the rate of adverse events is very low19. Systemic 
absorption occurs to varying degrees measurable in both urine and plasma; plasma 
concentrations demonstrated to have measurable systemic β-blocking activity in adults have been 
reported.17,18,21 Based on this information, we recommend that timolol application should be 
limited to the dose for which safety data have been most often reported, 1 drop twice daily of 
timolol 0.5%.  Timolol is not recommended for the treatment of thick or deep IH, both because it 
is less effective and systemic absorption may be greater.18   Because of the potential for systemic 
exposure of topical application, pre-screening should be performed to assure that infants are 
healthy with normal cardiopulmonary examinations via recent history and physical exam.  As 
with oral beta-blockers, temporary discontinuation is recommended if patients experience 
respiratory or gastrointestinal symptoms.   Infants under 3 months of age, and those whose 
history suggests ongoing IH growth, should be monitored via frequent visits or photographs 
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submitted by parents to assure that therapy does not need to be switched from topical to oral.  
Such follow-up visits can often be done via telemedicine.   
DISCUSSION: 
The COVID-19 pandemic has caused an abrupt shift from ambulatory visits to telemedicine 
platforms. This consensus statement provides guidance on timely treatment for patients with IH 
requiring early intervention while prioritizing patient safety.  While we acknowledge the benefits 
of in-person visits when health care systems are operating normally, there was group consensus 
that telehealth visits could provide an alternative method of evaluation and treatment as long as 
safeguards are in place to minimize risks.   Our recommendations are based upon first ensuring 
that there are no contraindications for therapy, documentation of a recent normal physical 
examination, and no signs or symptoms of active illness (Table 2). We suggest that these patients 
are amenable to initiation of therapy through a process of limited physical examination coupled 
with virtual counseling and education about the natural history, treatment options, administration 
of medication and potential adverse reactions to therapy.   
We recognize that there are other circumstances in which these recommendations may be 
applicable including natural disasters (e.g. earthquakes, hurricanes).  In addition, there are 
patients whose access to specialty care is severely limited due to geographic constraints (e.g. 
living many hours away from a center with expertise in the evaluation and management of IH) 
where these recommendations may prove beneficial.   
With or without telemedicine, all patients with IH require careful consideration of risks and 
benefits of any proposed treatment, discussion with families regarding treatment options, and 
recommendations and information about possible adverse events from prescribed medications 
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(Table 3).  For IH still in the rapid growth phase, we recommend particularly close follow-up, 
ideally within 1-2 weeks.  Telemedicine is particularly well-suited for these typically brief 
follow-up visits to assure that the IH is behaving as anticipated.  Parents should be advised to 
reach out to practitioners in the context of changes in the IH (e.g. ulceration, ongoing growth, 
development/progression of functional impairment). If the patient develops respiratory 
symptoms (e.g. cough, wheezing, respiratory distress), gastrointestinal symptoms (e.g. vomiting, 
diarrhea, decreased intake) or lethargy, medication should be immediately discontinued and a 
physician notified.22  Although infection with COVID-19 in young infants and toddlers most 
often does not result in severe symptoms, it can cause respiratory illness. Similar to other 
infections which can result in fever or respiratory symptoms, we recommend temporarily 
stopping propranolol in the setting of active infant COVID-19 infection until symptoms from the 
infection cease.2    Comprehensive counseling and communication of potential risks and benefits 
of treatment are of paramount importance both for anticipatory guidance and to help minimize 
side effects.  Online resources (Table 3) can be very helpful both in reinforcing education 
regarding the diagnosis of IH as well as specifics of treatment and possible side effects.  
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Table 1: Risk Level of IHs of Varying Types  
Risk Level   Clinical Examples and Reason(s) for Concern 
Highest 
 
 
 
 
 
 
 
 
 
 
 
 
 
High 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Intermediate 
 
 
 
 
 
Low 
 ●  Large (>5 cm) or segmental facial or scalp: 
○ higher risk of airway hemangiomas (if beard area), 
○ may be associated with PHACE syndrome, 
○ high risk of scarring and/or disfigurement. 
●  Large or segmental lumbosacral or perineal: 
○ may be associated with LUMBAR syndrome, 
○ high risk of ulceration and scarring. 
●  Multifocal IHs (≥5) and abdominal ultrasonography reveals hemangiomas: 
○ may be associated with abdominal compartment syndrome, high-output 
   congestive heart failure, and hypothyroidism. 
●  Periocular IH causing eyelid asymmetry, lid closure or ptosis, proptosis, or other   
    findings with potential impact on visual axis: 
○ risk of astigmatism, anisometropia, and amblyopia. 
 
●  Large segmental IH on trunk or extremities: 
○ risk of scarring and/or disfigurement. 
●  Any facial IH ≥2 cm (> 1 cm if ≤ 3 mo of age: 
○ high risk of scarring and/or disfigurement. 
●  Nasal tip or lip IH even if <1 cm: 
  ○  high risk of scarring and/or permanent distortion of anatomic landmarks. 
●  Oral 
  ○ risk of ulceration or bleeding, may interfere with feeding. 
●  Neck or scalp IH > 2 cm during growth phase: 
○ risk of ulceration (neck), 
○ risk of ulceration, scarring, and/or hair loss (scalp). 
●  Breast: 
 ○ risk of permanent changes in breast development (e.g. breast asymmetry) or 
    nipple contour. 
●  Ulcerated hemangioma (any site): 
○ risk of severe pain, scarring and/or disfigurement, and bleeding. 
●  Perineal IH (localized) without ulceration: 
○ potential for ulceration in this location. 
●  Trunk of extremity IH >2 cm especially in growth phase or if abrupt transition from 
     normal to affected skin (i.e., ledge effect): 
○ risk of scarring and/or disfigurement. 
●  IH <2 cm on trunk of extremities in areas easily covered by clothing. 
●  IH on trunk of extremities >2 cm if gradual transition from normal to affected skin. 
 
   
(Reprinted with permission from: Krowchuk DP, Frieden IJ, Mancini AJ, et al. 
Clinical Practice Guideline for the Management of Infantile Hemangiomas. 
Pediatrics. 2019 Jan;143: pii: e20183475. doi: 10.1542/peds.2018-3475.) 
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Table 2: Risk stratification when considering beta-blocker treatment 
Group 1 (Standard risk):  May consider telemedicine initiation of oral or topical beta-blocker 
therapy* as long as infant does not have additional features listed for Group 2 
 Adjusted gestational age > 5 weeks 
 Normal birth weight  
 Recent documented weight (within 2 weeks) 
 Normal cardiovascular exam within previous 4 weeks (including >1 documented HR 
after nursery discharge) 
 Normal respiratory exam within previous 4 weeks 
 Healthy in the 24-48 hours prior to  scheduled telemedicine visit (especially, no 
respiratory and gastrointestinal signs and symptoms 
 IH pattern and distribution does not confer risk of PHACE or LUMBAR syndrome 
 Lack of ulceration or minimal/superficial ulceration 
 Caregiver is able to understand instructions and demonstrate comprehension (e.g. by 
repeating instructions provided during visit) 
 Multiple IH with normal liver ultrasound and without cutaneous IH conferring risks noted 
in Group 2 
Group 2 (Higher risk):  Recommend in-person evaluation unless local circumstances make this 
impossible prior to initiation of systemic beta-blocker therapy** 
 Corrected gestational age  <5 weeks  
 Abnormal cardiovascular exam or investigations OR those who lack documentation of 
this in the post-natal period 
 Medium to high risk of PHACE (i.e. large segmental facial or scalp IH in segments S1, 
S3, S4) 
 Medium to high risk of LUMBAR syndrome (i.e. segmental perineal and/or lumbosacral  
body IH +/- visible associated anatomic abnormalities 
 Significant IH ulceration 
 Ongoing  poor oral feeding or poor weight gain 
 IH with symptoms of airway compromise (e.g. stridor) or bilateral S3 (beard area IH at 
high risk for airway IH). 
 Known pulmonary disease  including ongoing respiratory compromise (e.g. dyspnea, 
frequent wheezing or history of bronchospasm) 
 Persistent or ongoing hypoglycemia  
 Known or suspected congenital heart disease or suggestive symptoms 
o Known or suspected aortic coarctation 
o History of pathologic heart murmur or abnormal echocardiogram 
o Ongoing diaphoresis 
o Ongoing tachypnea 
o Ongoing tachycardia 
o History of syncope 
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 Extensive hepatic hemangiomas including those resulting in consumptive hypothyroidism 
or congestive heart failure 
 Known brain malformation 
 Family history in first degree relative of:  
o Congenital heart disease 
o Sudden death or arrhythmia  
 Maternal history of connective tissue disorder (e.g. systemic lupus, Sjogren syndrome, 
polymyositis, or other) 
* In ordinary circumstances infants are being seen regularly for well-child visits by primary 
care providers, who weigh and measure infants and perform heart and lung examinations as a 
standard part of their care.   If these examinations are not occurring due to disruptions in 
healthcare, it becomes much more difficult to ascertain whether there is a normal 
cardiovascular or pulmonary examination, if normal growth is occurring and other baseline 
characteristics.  In such cases decisions about initiating therapy must be done on a case-by-
case basis.   
**During this pandemic and other unusual circumstances, in-person visits may not be 
possible in a timely fashion.  In these settings, triage and management decisions need to be 
made on a case by case basis, ideally in conjunction with relevant specialists as needed (e.g. 
ENT, cardiology, etc).  
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Table 3 Online Infantile Hemangioma Resources* 
 
General Hemangioma Information 
• https://pedsderm.net/site/assets/files/1028/2_spd_infantile_hemangiomas_web_final.pdf 
• https://hemangiomaeducation.org/infantile-hemangiomas/ 
• https://en.wikipedia.org/wiki/Hemangioma 
• https://www.aap.org/en-us/advocacy-and-policy/aap-health-initiatives/Infantile-
Hemangiomas/Pages/default.aspx 
 
Beta-Blocker Therapy Information 
• https://pedsderm.net/site/assets/files/1028/12_spd_propranolol_color_web-final.pdf 
• https://hemangiomaeducation.org/systemic-treatment/ 
• https://hemangiomaeducation.org/topical-and-local-treatment/ 
• https://hemangiomaeducation.org/hemangioma-treatment/new-hig-propranolol-education-
video-for-caregivers 
 
*These links created or vetted by HIG members 
 
  
A
cc
ep
te
d 
A
rt
ic
le
 
This article is protected by copyright. All rights reserved 
 
 
Algorithm for Management 
